Related Experiment Videos
The UCLA experience with type I interferons in hairy cell leukemia
J A Glaspy1, A D Jacobs, D W Golde
1Department of Medicine, UCLA School of Medicine 90024.
Leukemia
|April 1, 1987
Summary
Recombinant interferons show high efficacy in treating hairy cell leukemia, with most patients achieving hematological improvement within six months. Different interferon types demonstrated varying response rates in clinical trials.
Area of Science:
- Oncology
- Hematology
- Immunotherapy
Background:
- Hairy cell leukemia is a rare B-cell malignancy.
- Interferon therapy has been explored for hairy cell leukemia treatment.
Purpose of the Study:
- To evaluate the efficacy and response rates of different types of interferon in patients with hairy cell leukemia.
- To present data on the rapidity of response, duration of follow-up, and toxicity.
Main Methods:
- Clinical trials involving fifty-one patients with hairy cell leukemia.
- Treatment with recombinant alpha-2b-interferon, lymphoblastoid alpha-N1-interferon, and recombinant beta-serine-interferon.
- Assessment of hematological improvement and response duration.
Main Results:
- Recombinant alpha-2b-interferon achieved a 96% hematological improvement rate.
- Lymphoblastoid alpha-N1-interferon showed a 69% response rate.
- Recombinant beta-serine-interferon demonstrated a 71% response rate in early trials.
- Most patients achieved improvement within six months, with all responders improving within one year.
Conclusions:
- Interferon therapy, particularly recombinant alpha-2b-interferon, is effective in achieving hematological improvement in hairy cell leukemia.
- Rapid responses are observed, with most patients responding within six months.
- Further analysis of follow-up duration and toxicity is warranted.